Table 2. Treatment modalities administered to patients with confirmed Middle East respiratory syndrome-coronavirus infection.
| Variable | Total (N = 186) | Survivors (N = 153) | Deceaseda (N = 33) |
|---|---|---|---|
| Antiviral agents - no. (%) | 138 (74.2) | 113 (73.9) | 25 (75.8) |
| Initiation of antiviral agents within 48 h. after symptom onset | 26 (14.0) | 18 (11.8) | 8 (24.2) |
| Proportion of each regimen (%) | |||
| Interferon + ribavirin + lopinavir/ritonavir | 81.1 | 81.4 | 80.0 |
| Interferon + ribavirin | 12.7 | 14.1 | 4.0 |
| Ribavirin + lopinavir/ritonavir | 5.0 | 2.6 | 16.0 |
| Ribavirin | 0.7 | 0.8 | 0 |
| Lopinavir/ritonavir | 0.7 | 0.8 | 0 |
| Antibiotics - no. (%) | 140 (75.3) | 109 (71.2) | 31 (93.9) |
| Mechanical ventilation | 45 (24.2) | 20 (13.1) | 25 (75.8) |
| Haemodialysis - no. (%) | 15 (8.1) | 5 (3.3) | 10 (30.3) |
| Extracorporeal membrane oxygenation - no. (%) | 13 (7.0) | 10 (6.5) | 3 (9.1) |
| Convalescent serum - no. (%) | 7 (3.8) | 6 (3.9) | 1 (3.0) |
| Intravenous immunoglobulin - no. (%) | 5 (2.7) | 2 (1.3) | 3 (9.1) |
aDeceased were determined at 28 days since the onset of symptoms.